A5029463040- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- RNA modifications and cancer
- Ubiquitin and proteasome pathways
- Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Tumors and Oncological Cases
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Research and Treatments
- Oral and Maxillofacial Pathology
- Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Genetic factors in colorectal cancer
- SARS-CoV-2 detection and testing
Centre Hospitalier Universitaire de Nice
2016-2025
Université Côte d'Azur
2016-2025
Institut de Recherche sur le Cancer et le Vieillissement de Nice
2016-2025
Inserm
2016-2025
Centre National de la Recherche Scientifique
2016-2025
Hôpital Pasteur
2016-2025
Institut de Biologie Valrose
2021-2025
Scientific Research Institute of Experimental and Clinical Medicine
2008-2024
Royal Hobart Hospital
2024
Centre Antoine Lacassagne
2014-2023
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer. Migration of circulating tumor cells (CTCs) into the blood stream an early event that occurs during carcinogenesis. We aimed to examine presence CTCs in complement CT-scan COPD patients without clinically detectable cancer as first step identify new marker diagnosis. The was examined by ISET filtration-enrichment technique, 245 subjects cancer, including 168 (68.6%) patients, and 77 (31.4%), 42 control smokers 35...
Abstract Comparison of the efficacy different enrichment methods for detection circulating tumor cells (CTCs) before radical surgery is lacking in non‐small‐cell lung carcinoma (NSCLC) patients. Detection and enumeration CTCs 210 consecutive patients undergoing NSCLC were evaluated with CellSearch Assay™ (CS), using Epithelial Cell Kit, by isolation size epithelial (ISET) method, double immunolabeling anti‐cytokeratin anti‐vimentin antibodies. detected 144 (69%) CS and/or ISET 104 (50%) 82...
Recurrence rates after surgery for non-small cell lung cancer (NSCLC) range from 25 to 50% and 5-year survival is only 60-70%. Because no biomarkers are predictive of recurrence or the onset metastasis, pathological TNM (pTNM) staging currently best prognostic factor. Consequently, preoperative detection circulating tumour cells (CTCs) might be useful in tailoring therapy. The aim this study was characterize morphologically any non-haematological (CNHCs) patients undergoing NSCLC using...
Detection of circulating tumor cells (CTCs) morphologically may be a promising new approach in clinical oncology. We tested the reliability cytomorphologic to identify CTCs: 808 blood samples from patients with benign and malignant diseases healthy volunteers were examined using isolation by size epithelial cell (ISET) method. Cells having nonhematologic features (so-called [CNHCs]) classified into 3 categories: CNHCs features, uncertain features. found 11.1% 48.9% nonmalignant pathologies,...
With the ongoing need to improve therapy for non-small cell lung cancer (NSCLC) there has been increasing interest in developing reliable preclinical models test novel therapeutics. Patient-derived tumor xenografts (PDX) are considered be interesting candidates. However, establishment of such model systems requires highly specialized research facilities and introduces logistic challenges. We aimed establish an extensive well-characterized panel NSCLC xenograft context a long-distance network...
Previous studies indicate that endothelial injury, as demonstrated by the presence of circulating cells (CECs), may predict clinical outcome in cancer patients. In addition, soluble CD146 (sCD146) reflect activation angiogenesis. However, no study has investigated their combined value patients undergoing resection for non-small cell lung (NSCLC).Data were collected from preoperative blood samples 74 who underwent NSCLC. Circulating defined, using CellSearch Assay, CD146+CD105+CD45-DAPI+....
The aim of this study was to compare the detection BRAF(V600E) by immunohistochemistry (IHC) using a mutation-specific antibody with molecular biology methods for evaluation papillary thyroid carcinoma (PTC) patients.This concerned 198 consecutive conventional PTC patients, which majority were women (133/198; 67%), mean age 56 years (range 19-79 years). BRAF mutation analysis performed DNA-based (direct sequencing, pyrosequencing, and SNaPshot) IHC (VE1 antibody) methods. sensitivity...
// Marius Ilie 1, 2, 3 , Catherine Butori Sandra Lassalle Simon Heeke 2 Nicolas Piton 4 Jean-Christophe Sabourin Virginie Tanga Kevin Washetine Elodie Long-Mira Priscilla Maitre Nathalie Yazbeck Olivier Bordone Lespinet Sylvie Leroy 5 Charlotte Cohen 6 Jérôme Mouroux Charles Hugo Marquette Véronique Hofman and Paul 1 Laboratory of Clinical Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d'Azur, Nice, France IRCAN Inserm U1081/CNRS 7284, Hospital-related Biobank...
// Sandra Lassalle 1, 2, 3, 4, 5, * , Joséphine Zangari Alexandra Popa 6 Marius Ilie 5 Véronique Hofman Elodie Long Martine Patey 7 Frédérique Tissier 8 Geneviève Belléannée 9 Hélène Trouette Bogdan Catargi 10 Isabelle Peyrottes 11 Jean-Louis Sadoul 12 Olivier Bordone Christelle Bonnetaud Catherine Butori Alexandre Bozec 13 Nicolas Guevara José Santini Imène Sarah Hénaoui Géraldine Lemaire 14 Blanck...
The number of genomic alterations required for targeted therapy non-squamous non-small cell lung cancer (NS-NSCLC) patients has increased and become more complex these last few years. These molecular abnormalities lead to treatment that provides improvement in overall survival certain patients. However, treated tumors inexorably develop mechanisms resistance, some which can be with new therapies. characterization the needs performed a short turnaround time (TAT), as indicated by...
Background/Objectives: Immune checkpoint inhibitors (ICIs) benefit some lung cancer patients, but their efficacy is limited in advanced adenocarcinoma (LUAD) with EGFR mutations (EGFRm), largely due to a non-immunogenic tumour microenvironment (TME). Furthermore, EGFRm LUAD patients often experience increased toxicity ICIs. CD73, an ectonucleotidase involved adenosine production, promotes immune evasion and could represent novel therapeutic target. This study investigates CD73 expression...
This article provides an update on the current state of decarbonization efforts in biobanking, reflecting evolving discussions at annual meetings International Society for Biological and Environmental Repositories (ISBER). Following roundtable 2021 2023 meetings, 2024 ISBER meeting, which was held Melbourne, Australia, featured a symposium, workshop, posters dedicated to decarbonization, highlighting its growing significance global scale. The introduction term "green biobanking" this meeting...
Abstract Background Adjuvant immunotherapy (AIO) improved recurrence‐free survival (RFS) in patients with resected stages III–IV melanoma. Real‐world data, especially elderly patients, as well optimal management of who relpases, are still limited. Objectives To evaluate real‐world outcomes AIO a cohort melanoma patients. Methods We conducted monocentric, retrospective, observational study that included treated (nivolumab or pembrolizumab) for III/IV The primary endpoint was RFS. Subgroup...
Case ReportA 68-year-old woman (patient 1) was diagnosed in October 2010 with a melanoma of the back superficial spreading subtype, Breslow thickness 1.1 mm.Ulceration and mitoses were not observed.In June 2011, she developed right axillary lymph node metastases that treated by surgery.In September patient multiple subcutaneous pulmonary metastases.A muta-tion analysis showed no BRAF mutation at position V600 NRAS mutations positions G12 Q61.Treatment dacarbazine failed to stop progression...